

Moxibustion for the Prevention of Hemorrhagic Cystitis After Allo-HSCT

NCT06198517

Status	RECRUITING
Phase	Not Applicable
Sponsor	Yi Zhang
Enrollment	266 participants

Key Eligibility Criteria

Inclusion (3)

- Patients are fully aware of the study, participate voluntarily and sign the informed consent form (ICF);
- Age: 14-60 years;
- Patients with pernicious blood diseases undergoing allo-HSCT using the MAC protocol or patients with severe aplastic anemia (Severe aplastic anemia; severeaplasticanimin, SAA) undergoing allo-HSCT;

Exclusion (3)

- refuse to participate in this clinical study;
- The corresponding skin at the moxibustion site is broken or sensitive;
- allo-HSCT pretreated with the RIC program;

Locations (4 total)

Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Zhengzhou, Henan, China
Yi Zhang, Wuhan, Hubei, China
Hematology Department, The First People's Hospital of Yunnan, Kunming, Yunnan, China
... and 1 more locations